Study on the expression of matrix metalloproteinase-2 mRNA in human gastric cancer

Table 1 Clinical features of cases and expression of MMP-2 mRNA

No.	Age/sex	Location	Histology	Clinical stageb	MMP2 mRNA expression
					T	2 cm	≥ 5 cm
1a	64/M	Pylorus	Poor	T1N0M0 (I)	-	-	-
2	48/M	Body	Poor	T4N0M0 (IV)	+	+	-
3	72/F	Lesser curve	Poor	T4N2M1 (IV)	+	+	-
4	75/F	Lesser curve	Poor	T3N0M0 (II)	+	+	-
5	71/M	Body	Poor	T2N1M0 (IVA)	+	+	-
6	63/M	Lesser curve	Well	T4N2M0 (IV)	-	-	+
7a	73/F	Lesser curve	Poor	T1N1M0 (IIIA)	+	-	-
8a	46/M	Lesser curve	Poor	T1N0M0 (I)	-	-	-
9	60/F	Body	Poor	T3N0M0 (II)	+	-	-
10	57/M	Pylorus	Poor	T3N1M1 (IV)	+	+	+
11	53/M	Body	Poor	T4N1M0 (IV)	+	+	-
12a	72/F	Antrum	Poor	T1N0M0 (I)	-	-	-
13	59/M	Body	Poor	T3N2M0 (IIIB)	+	-	-
14a	38/M	Antrum	Well	T1N0M0 (I)	-	-	-
15	66/F	Cardia	Poor	T3N1M0 (IIIA)	+	+	+
16	55/M	Antrun	Well	T2N0M0 (IB)	-	-	-
17	74/M	Body	Poor	T4N2M1 (IV)	+	+	+
18	67/M	Cardia	Well	T3N2M0 (IVB)	-	-	-
19	67/F	Body	Poor	T4N2M1 (IV)	+	+	+
20	56/M	Body	Poor	T4N2M1 (IV)	+	+	+

T: Tumor tissues; 2 cm: 2 cm adjacent tissue from tumor; ≥ 5 cm: 5 cm or over 5 cm adjacent tissue from tumor.

^a: Early gastric cancer. Poor: Poorly differentiated adenocarcinoma; Well: Well differentiated a denocarcinoma.

^b: According to the American Joint Commission Staging of Gastric Cancer.

Table 2 OD of MMP-2 cDNA signals in early and advanced cancer (x^-± s_x^-)

	T	2 cm	≥ 5 cm
Early cancer (n = 5)	1.63 ± 0.42	1.07 ± 0.29	1.50 ± 0.22
Advanced cancer (n = 15)	6.63 ± 1.12a	2.80 ± 0.34a	1.94 ± 0.29

^aP < 0.05, vs early cancer.